No FDA-approved stem-cell therapy exists for SMA. Two proven disease-modifying therapies are FDA-approved — nusinersen (slows progression) and onasemnogene abeparvovec gene therapy (durable motor benefit, especially in infants). Stem-cell therapies are investigational and lack comparable evidence; claims of approval or equivalence are false.
Spinal Muscular Atrophy is a genetic neuromuscular disorder caused by SMN1 mutations, leading to insufficient survival motor neuron protein and progressive motor-neuron loss and muscle atrophy. Stem-cell research explores neurogenic cells to support or replace motor neurons and placental mesenchymal stem cells to secrete neuroprotective factors and reduce neuroinflammation. Because SMA is genetic, cellular approaches that do not correct the underlying SMN deficiency may offer limited long-term benefit. This distinguishes SMA from acquired disorders, and helps explain why approved gene-targeted therapies dominate care. Trials are very few; reported outcomes focus on motor-function stabilisation rather than recovery.
Съм ли кандидат? → · Spinal Muscular Atrophy: full overview → · Цена Гръбначна мускулна атрофия → · Cost →
Медицински преглед от редакционния екип на StemCellAtlas с Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) на партньорската клиника Stem Plus (София), спрямо ISSCR, FDA и EMA указания. Educational information, not medical advice; figures indicative.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка